Process for Manufacturing Glatiramer Acetate Product
Teva Pharmaceutical Industries, Ltd.
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,155,775 | Process for Manufacturing Glatiramer Acetate Product In force · High confidence UsedRemaining | Teva Pharmaceutical Industries Ltd. | In force | High confidence | ||
| US 9,763,993 | Process for Manufacturing Glatiramer Acetate Product In force · Medium confidence | Teva Pharmaceutical Industries, Ltd. | In force | Medium confidence | ||
| Application 15/471,765 | Process for Manufacturing Glatiramer Acetate Product Abandoned Abandoned Jun 7, 2017 | Teva Pharmaceutical Industries, Ltd. | Abandoned | Abandoned Jun 7, 2017 | ||
| Application 15/510,156 | Process for Manufacturing Glatiramer Acetate Product Abandoned Abandoned May 1, 2018 | Teva Pharmaceutical Industries Ltd. | Abandoned | Abandoned May 1, 2018 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Teva Pharmaceutical Industries, Ltd..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.